KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $8.4 billion.

  • Regeneron Pharmaceuticals' Cash & Current Investments fell 13.81% to $8.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $33.3 billion, marking a year-over-year decrease of 18.78%. This contributed to the annual value of $9.0 billion for FY2024, which is 16.90% down from last year.
  • According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Cash & Current Investments is $8.4 billion, which was up 13.04% from $7.5 billion recorded in Q2 2025.
  • Regeneron Pharmaceuticals' Cash & Current Investments' 5-year high stood at $10.8 billion during Q4 2023, with a 5-year trough of $3.5 billion in Q1 2021.
  • In the last 3 years, Regeneron Pharmaceuticals' Cash & Current Investments had a median value of $9.0 billion in 2024 and averaged $9.3 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 101.23% in 2022, then decreased by 23.85% in 2025.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Cash & Current Investments stood at $5.7 billion in 2021, then spiked by 35.96% to $7.7 billion in 2022, then spiked by 40.07% to $10.8 billion in 2023, then declined by 16.90% to $9.0 billion in 2024, then declined by 13.81% to $8.4 billion in 2025.
  • Its last three reported values are $8.4 billion in Q3 2025, $7.5 billion for Q2 2025, and $8.3 billion during Q1 2025.